Indeed, combination of CAR-NK-92 targeting prostate-specific membrane antigen (PSMA) with an anti-PD-L1 mAb (Atezolizumab) resulted in increased in vitro CAR-NK-92 mediated killing of C4-2 cells (a human castration-resistant prostate cancer (CRPC) cell line expressing PSMA) and primary tumor cells from a CRPC patient. The gene discussed is FOLH1; the disease is neoplasm.